Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
REVENUES:    
Total revenues $ 80,942,625 $ 42,219,783
Cost of product revenue 79,769,341 61,291,426
Gross profit (loss) 1,173,284 (19,071,643)
OPERATING EXPENSES:    
Research and development 3,646,060 5,907,013
Plasma center operating expenses 12,288,723 4,170,051
Amortization of intangible assets 715,353 715,353
Selling, general and administrative 42,896,889 35,050,817
Total operating expenses 59,547,025 45,843,234
LOSS FROM OPERATIONS (58,373,741) (64,914,877)
OTHER INCOME (EXPENSE):    
Interest income 34,532 288,126
Interest expense (13,056,834) (11,985,066)
Gain on extinguishment of debt 0 991,797
Other expense (251,575) (128,528)
Other expense, net (13,273,877) (10,833,671)
NET LOSS $ (71,647,618) $ (75,748,548)
BASIC LOSS PER COMMON SHARE (in dollars per share) $ (0.51) $ (0.88)
DILUTED LOSS PER COMMON SHARE (in dollars per share) $ (0.51) $ (0.88)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic (in shares) 139,578,538 86,145,052
Diluted (in shares) 139,578,538 86,145,052
Product Revenue [Member]    
REVENUES:    
Total revenues $ 80,799,791 $ 42,076,949
License Revenue [Member]    
REVENUES:    
Total revenues $ 142,834 $ 142,834